Voyageur Pharmaceuticals Ltd VYYRF

Primary Symbol: V.VM

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > New Press Release - Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors

<< Previous

Bullboard Posts

Next >>

Comment by WarrantOfficeron Dec 21, 2023 7:40pm

101 Views

Post# 35796850

RE:RE:RE:New Press Release - Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors

Trust is earned. IMO, management has not yet earned it. Investors whom paid for their shares are no doubt questioning if management deserves the DSU's. We are just coming off a year low SP of .035

Was the 2023 AGM zoomed? I did receive the voting proxies, read nothing about the AGM being zoomed.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”